Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Dr Reddy's: Dismal performance - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • May 29, 2004

    Dr Reddy's: Dismal performance

    Dr Reddy's announced poor March quarter and FY04 results yesterday. The net sales of the company were down 1.4% in 4QFY04, while net profit was down by 91% on a standalone basis. The company incurred operating loss of Rs 195 m. The performance for the full year too, was not very encouraging, with net profit plummeting by 29% to Rs 2,830 m. Although revenues of the company in FY04 were up 9%, the operating profit of the company fell by 33% YoY. The operating margins plummeted to 18% compared to 29.4% in FY03.

    (Rs m) 4QFY03 4QFY04 Change FY03 FY04 Change
    Net sales 4,026 3,969 -1.4% 15,286 16,666 9.0%
    Other income 139 159 14.0% 465 757 63.1%
    Expenditure 2,830 4,164 47.1% 10,796 13,658 26.5%
    Operating profit (EBDITA) 1,196 (195) -116.3% 4,490 3,008 -33.0%
    Operating profit margin (%) 29.7% -4.9%   29.4% 18.0%  
    Interest 5 6 24.0% 35 15 -57.1%
    Depreciation 164 201 22.8% 608 717 17.9%
    Profit before tax 1,167 (243) - 4,312 3,033 -29.6%
    Tax (29) (351) - 391 202 -48.4%
    Profit after tax/(loss) 1,196 107 -91.0% 3,921 2,832 -27.8%
    Net profit margin (%) 29.7% 2.7%   25.7% 17.0%  
    No. of shares (m)       76.5 76.5  
    Diluted earnings per share (Rs)*       51.3 37.0  
    (* annualised)            

    On consolidated basis, revenues increased by 12% YoY and the net profit was down 31%. Dr. Reddy's consolidated operating margin stood at 14.8%, down from 25.2% in FY03. The company's dismal performance has come on back of its poor showing in the North American markets.

    (Rs m) FY03 FY04 Change
    Net sales 17,289 19,334 11.8%
    Other income 538 894 66.0%
    Expenditure 12,927 16,471 27.4%
    Operating profit (EBDITA) 4,362 2,863 -34.4%
    Operating profit margin (%) 25.2% 14.8%  
    Interest 39 19 -51.4%
    Depreciation 751 1,025 36.4%
    Profit before tax 4,110 2,713 -34.0%
    Tax 461 202 -56.2%
    Profit after tax/(loss) 3,649 2,511 -31.2%
    Net profit margin (%) 21.1% 13.0%  
    No. of shares (m) 76.5 76.5  
    Diluted earnings per share (Rs)* 47.7 32.8  
    P/E ratio (x)   27.0  
    (* annualised)      

    Operating expenses expanded at a faster clip as compared to revenues. The raw material costs went up by a substantial 23%. Consequently, raw material cost as a percentage of revenues went up from 30% to 34% mainly on account of increased contribution of API's in the total business. The company has also increased the R&D expenses in FY04 by about 38% YoY. R&D expenditure now stands at 9.9% of total revenues compared to 7.8% in FY03, the highest among Indian companies. A one-time charge of Rs 385 m on amolodipine project and government charges also reduced the company's margins substantially. The following table shows the cost structure of the company on a consolidated basis.

    Cost structure consolidated…
    Rs m FY03 FY04 Change % of sales FY04
    Raw material 4,976 6,208 24.8% 32.1%
    Staff cost 1,794 2,366 31.9% 12.2%
    Excise duty expenses 153 59 -61.5% 0.3%
    R&D Expenses 1,324 1,826 37.9% 9.4%
    Selling Expenses 1,594 1,968 23.4% 10.2%
    Provisions 35 - -100.0% 0.0%
    Other expenditure 3,052 4,045 32.6% 20.9%
    Total 12927 16471 27.4% 85.2%

    Dr. Reddy's dismal performance can be attributed to the change in the business mix. The low margin API business has outpaced the branded formulation and generics business in the fourth quarter as well as in the full year. Infact, on a consolidated basis, the API business has grown by 20%, while the generics business grew by a marginal 1%. It should be noted that in API business, which is more like a commodity business, margins are considerably lower compared to generics or formulations business. The generics business of the company took a toll in the US because of increasing competition in Fluoxetine and Tizanidine tablets. Also, the lack of new product launches in the US also contributed to the woes of the company. The amolodipine setback was also a negative for its generic plans. While the generics business of the company in US has come down by 9% in FY04, the company was able to expand its business in the European markets and Russian markets.

    Business mix consolidated…
    FY03 FY04 Change % of sales FY04
    APIs 6,341 7,629 20.3% 39.5%
    Branded Formulations 6,860 7,507 9.4% 38.8%
    Generics 4,284 4,338 1.3% 22.4%
    Diagnostic and other services 428 411 -4.0% 2.1%
    Others 157 297 89.2% 1.5%

    In the Indian market, Dr. Reddy's was able to outperform and grew by 10% compared to 7.3% growth in overall market. The key brands of the company have shown good performance and were led its growth in the Indian markets. These brands contributed 52% of the total branded formulation sales of the company. It should be noted that the branded formulations market in India had a good time in FY04 compared to a very lean period in FY03.

    Dr. Reddy's high-risk business of patent challenges has cost it dear in FY04, with no success after fluoxetine. Notwithstanding this, the company has filed 13 ANDA's with USFDA in FY04, out of which 8 were Para IV filings, which again shows the company's aggressiveness in the US market. At the current price of Rs 887, the stock is trading at a P/E of 27x FY04 earnings, which seems to be on a higher side with a near term view. The margins of the company in FY05 are unlikely to improve substantially, since Dr. Reddy's is not gaining any ground in generics and formulations. On the positive side, increased R&D expenses reiterate the company's focus on research, a key factor for success over the long term. Also, the acquisition of Trigenisis in the US will enable the company to enter the lucrative dermatology market in the US, which can drive revenues further. In the near term, investors should view the stock with caution considering the company's high risk strategy of patent challenges, which makes its performance prone to volatility. Over the long term, we remain positive on Dr. Reddy's prospects considering its research strengths.



    Equitymaster requests your view! Post a comment on "Dr Reddy's: Dismal performance". Click here!


    More Views on News

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

    Sep 12, 2016

    Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)


    • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Compare Company With Charts